In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Palisade Bio Inc (NASDAQ: PALI) closed the day trading at $2.0 up 19.05% from the previous closing price of $1.68. In other words, the price has increased by $19.05 from its previous closing price. On the day, 21.89 million shares were traded. PALI stock price reached its highest trading level at $2.16 during the session, while it also had its lowest trading level at $1.7144.
Ratios:
For a better understanding of PALI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.55 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PALI now has a Market Capitalization of 245119424 and an Enterprise Value of 13149304.
Stock Price History:
The Beta on a monthly basis for PALI is 1.43, which has changed by -0.42528737 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, PALI has reached a high of $4.32, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 133.17%, while the 200-Day Moving Average is calculated to be 111.31%.
Shares Statistics:
Over the past 3-months, PALI traded about 6.72M shares per day on average, while over the past 10 days, PALI traded about 30872340 shares per day. Insiders hold about 0.24% of the company’s shares, while institutions hold 6.18% stake in the company. Shares short for PALI as of 1757894400 were 497201 with a Short Ratio of 0.07, compared to 1755216000 on 424351. Therefore, it implies a Short% of Shares Outstanding of 497201 and a Short% of Float of 5.47.
Earnings Estimates
The stock of Palisade Bio Inc (PALI) is currently being evaluated by 3.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.32 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.55 and -$1.84 for the fiscal current year, implying an average EPS of -$1.72. EPS for the following year is -$1.24, with 3.0 analysts recommending between -$0.72 and -$1.77.
